Evidence map›Paper›PMID 32544082›Full record

Trial reportAging2020

Combined impact of body mass index and glycemic control on the efficacy of clopidogrel-aspirin therapy in patients with minor stroke or transient ischemic attack.

Zimo Chen, Jinglin Mo, Jie Xu, Anxin Wang, Haiqiang Qin, Huaguang Zheng, Liping Liu, Xia Meng, Hao Li, Yongjun Wang

Open access · greenAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Zimo ChenDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Jinglin MoDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Jie XuDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Anxin WangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Haiqiang QinDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Huaguang ZhengDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Liping LiuDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xia MengDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Hao LiDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yongjun WangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Capital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA single index of body mass index (BMI) may not fully address its impact on anti-platelet therapy. We aimed to elucidate the combined impact of BMI and dysglycemia expressed by glycated albumin (GA) on efficacy of clopidogrel-aspirin therapy among minor stroke (MS) or transient ischemic attack (TIA) patients.

resultsPatients with overweight/obesity and low GA levels still benefited from clopidogrel-aspirin therapy for stroke recurrence (Hazard ratio [HR]: 0.48, 95 % confidence interval [CI]: 0.28-0.82), so did those with high GA levels but low/normal weight (HR: 0.67, 95 % CI: 0.45-0.99). However, patients with both overweight/obesity and high GA levels did not benefit from clopidogrel-aspirin therapy (HR: 0.89, 95 % CI: 0.59-1.33).

conclusionsCompared with aspirin alone, efficacy of clopidogrel-aspirin therapy for stroke still exists in overweight/obesity patients with normal glycemic control.

methodsIn Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events trial, 3044 patients with available baseline GA were recruited. Low/normal weight and overweight/obesity were defined as BMI < 25 kg/m

Indexed as

Body Mass IndexAgedAspirinClopidogrelDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFemaleFollow-Up StudiesGlycated Serum AlbuminGlycation End Products, AdvancedGlycemic ControlHumansIschemic Attack, TransientMaleMiddle AgedAspirinClopidogrelGlycated Serum AlbuminGlycation End Products, AdvancedPlatelet Aggregation InhibitorsSerum Albuminbody mass indexclopidogrelglycated albuminischemic stroke

Identifiers

PMID32544082
PMCPMC7343455
OpenAlexW3034278931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.